37 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27326332	66	Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.	Bristol-Myers Squibb
24462665	30	Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR¿ agonists.	Glaxosmithkline
17964792	31	Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.	Nippon Shinyaku
18280733	27	Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.	Nippon Shinyaku
15546740	41	Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.	Eli Lilly
12951090	57	O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.	Merck Research Laboratories
22133631	76	Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.	Kyorin Pharmaceutical
21377875	19	Synthesis and pharmacological evaluation of novel benzoylazole-based PPARa/κ activators.	Dainippon Sumitomo Pharma
21130649	11	Development of a new class of benzoylpyrrole-based PPARa/¿ activators.	Dainippon Sumitomo Pharma
20822906	11	A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.	Seoul National University
20452212	26	Glycine amides as PPARalpha agonists.	Bayer-Schering Pharma
20218621	131	Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).	Bristol-Myers Squibb
20079636	78	Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.	Glaxosmithkline
19530681	79	Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.	Merck Research Laboratories
19507861	18	Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma a	Merck Research Laboratories
19349176	137	Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.	F. Hoffmann-La Roche
18947994	102	The discovery of equipotent PPARalpha/gamma dual activators.	Glaxosmithkline
18060776	100	Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.	Glaxosmithkline
17157013	74	Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.	Bayer Pharmaceuticals
16275077	27	Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.	University of Tokyo
16107150	39	Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.	Università
15801817	32	Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.	Merck Research Laboratories
15163205	94	(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.	Merck Research Laboratories
12699745	49	Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.	Glaxosmithkline
11677135	21	Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.	Glaxosmithkline
11354382	42	Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.	Glaxosmithkline
10691680	72	The PPARs: from orphan receptors to drug discovery.	Glaxo Wellcome Research & Development
10508427	42	A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.	Glaxo Wellcome Research & Development
31320147	22	Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR?)-selective agonists.	Okayama University
31930920	69	The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.	Terns Pharmaceuticals
30594433	90	Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.	Inception Sciences
8576907	13	The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.	Glaxo Wellcome Research and Development
29446942	98	Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.	Inventiva
28539218	25	Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor?/? (PPAR?/?) dual agonists.	The University of Tokyo
8474008	58	Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.	Virginia Commonwealth University
19843080	43	The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.	Pfizer